Neurosense Therapeutics Ltd

NASDAQ NRSN
$1.18 0.08 7.27%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Rating Finrange

Index: 10 %
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
20.13M
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
16.83M
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
21.65M
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-1.67 %

Upcoming events Neurosense Therapeutics Ltd

All events
No upcoming events scheduled

Stock chart Neurosense Therapeutics Ltd

Stock analysis Neurosense Therapeutics Ltd

Indicator Company Industry
P/E (LTM) Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
-3.05 -1.30
P/BV (LTM) Shows the ratio of the market price of the share to the current book value.
8.64 1.15
EV/EBITDA (LTM) Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
-3.86 -0.75
Net Debt/EBITDA (LTM) A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
0.76 0.42
ROE (LTM) Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
-255.79 -50.00

Price change Neurosense Therapeutics Ltd per year

0.86$ 2.49$
Min Max

Summary analysis Neurosense Therapeutics Ltd

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Neurosense Therapeutics Ltd

Revenue and net income Neurosense Therapeutics Ltd

All parameters

About company Neurosense Therapeutics Ltd

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Address:
Building B, Herzliya, Israel, 4672562
Company name: Neurosense Therapeutics Ltd
Issuer ticker: NRSN
ISIN: IL0011809592
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2021-12-09
Sector: Healthcare
Industry: Biotechnology
Site: https://www.neurosense-tx.com